PHYSICIANS AGREE:The key to health and longevity is

INFLAMMATORY HEALTH

IMPORTANT NEW EXAMPLE:10,061 Patient CANTOS TrialInflammation = CV Benefit

Ridker et al. New Engl J Med, 377:1119-1131, 2017

VALIDATING THEINFLAMMATORYHYPOTHESIS

TARGETING INFLAMMATION TO REDUCE CVD RISK

CANTOSCanakinumab ANti-inflammatory Thrombosis Outcome Study

● Randomized, double-blind, placebo controlled

● Subjects:○ 10,061 cardiovascular patients, 39 countries○ Standard of care (including statins)

○ Elevated inflammation (CRP > 2 mg/L)

● Agent: Anti-inflammatory drug (canakinumab)

● Duration: 4 years

● Results:○ No change in lipids○ REDUCTION OF INFLAMMATION (CRP < 2 mg/L) =

■ Heart attacks & strokes ⬇ 25%■ Cardiovascular death ⬇ 31%■ All-cause mortality ⬇ 31%

Response to The CANTOS Trial:

- Dr. Steve Nissen, MD Chairman of Cardiovascular Medicine

Cleveland ClinicWashington Post, August 27, 2017

“It (this study) opens up an entirely new vista for the treatment of heart disease, because now everybody on the planet—in the

pharmaceutical industry and in research institutions like ours and at the National Institutes of Health—are going to be looking to find anti-

inflammatory therapies.”

8,179 Patient REDUCE-IT Trial• Cardiovascular patients on standard of care (including

aggressive statin therapy)

• Vascepa: EPA only fish oil drug: 4g per day

• MOA: primarily inflammation (hsCRP), modest effect on TG’s, endothelial function

• Primary Endpoint: Major Adverse Cardiovascular Events (MACE)

• 25% REDUCTION IN MACE (NEJM)• ROBUST SECONDARY ENDPOINT

RESULTS• WELL TOLERATED

Important New Example

Why not manage inflammatory health with other leading anti-inflammatories?

IBUPROFEN ASPIRIN CELECOXIB CORTICOSTEROID SACETAMINOPHEN

Because of the risk of dangerous

SIDE EFFECTSassociated with chronic use

IBUPROFEN ASPIRIN CELECOXIB CORTICOSTEROID SACETAMINOPHEN

HEART ATTACKS GI BLEEDS STROKES

IMMUNE COMPROMISE

and more...

LIVER DAMAGE

Because of the risk of dangerous

SIDE EFFECTSassociated with chronic use

There’s NO anti-inflammatory that’s safe for

CHRONIC USE

UNTIL NOW

ASTAXANTHINa safe anti-inflammatoryfor health and longevity *

WHAT IS ASTAXANTHIN?

Astaxanthin is a naturally occurring marine carotenoid found in salmon, microalgae, krill, lobster, and crab.

Carotenoids are natural pigments that impart coloration and support animal health and vitality.

Astaxanthin is responsible for turning salmon and shellfish pink.

WITHOUT ASTAXANTHIN, SALMON ARE:● Grey

● Small

● Have reproductive problems

● Prone to infections

● Too weak to swim upstream

ASTAXANTHIN SAFETYNo significant side effects have been reported in published human studies of astaxanthin

● FDA GRAS (Generally Recognized as Safe) designation

● Extensive safety testing

● Long history of use in humans and animals

been reported in published human

n humans

Source: ncbi.nlm.nih.gov

ASTAXANTHIN EFFICACY

Potent anti-inflammatory activity

● 1,600+ peer reviewed papers More than 50 peer reviewed papers published by Cardax team members

● 50+ human clinical trials20+ randomized, double blind, placebo controlled human POC

Focusing on the source of inflammation

Astaxanthin

MITOCHONDRIAL HEALTHMECHANISM OF ACTION

● Astaxanthin spans mitochondrial membrane

● Reduces pathological activation of inflammatory pathways by modulating oxidative stress in mitochondria

● Does not inhibit normal function

BIOLOGICAL LIPID BILAYER

ASTAXANTHIN

Liver HealthCardiovascular Health

Metabolic HealthHealth

Joint Health Longevity Mental Health

ASTAXANTHIN INFLAMMATORY HEALTH APPLICATIONS

COMMONALITIES

● Inflammation

● Oxidative Stress

ASTAXANTHIN IN HUMAN & ANIMAL STUDIES

● Reduces inflammation

● Improves lipid profiles

● Lowers blood pressure

● Decreases artery plaque formation in animals

KEY POINTS

ASTAXANTHIN & CARDIOVASCULAR

HEALTH

● Reduces inflammation

● Increases adiponectin levels

● Lowers blood glucose and insulin levels in animals

● Improves insulin signaling/response in animals

KEY POINTS

ASTAXANTHIN &METABOLIC

HEALTH

● Decreases liver fat (steatosis)

● Reduces inflammation and oxidative stress

● Decreases liver enzyme levels in animals

● Improves fibrosis and insulin response in animals

KEY POINTS

ASTAXANTHIN & LIVER HEALTH

● Reduces inflammation

● Lowers oxidative stress

● Decreases joint degeneration in animal OA model

● Reduces major inflammatory markers in animals

KEY POINTS

ASTAXANTHIN & JOINT HEALTH

Introducing Cardax astaxanthin supplement

SAFE ANTI-INFLAMMATORYFOR HEALTH AND LONGEVITY*

NOTFDA GRAS DESIGNATED

IBUPROFEN ASPIRIN CELECOXIB CORTICOSTEROID SACETAMINOPHEN

ZANTHOSYN EDUCATION

CREDIBLE RECOMMENDATIONS BASED IN SCIENCE

FOUNDATION: PHYSICIAN AWARENESS

● Industry research: 2/3 of consumer vitamin, mineral, and supplement sales catalyzed by physicians

● ZanthoSyn presented to 1,500+ physicians and other healthcare professionals

● Quality interactions: conferences, CMEs, meetings

● Strong interest in safely addressing inflammatory health

● Low cost: $40-$80 month (before insurance)

ZANTHOSYN CLINICAL TRIAL

TARGETING CARDIOVASCULAR INFLAMMATORY HEALTH

● Supports sales & marketing

● Serves as POC for Rx

● Patent(s) pending

CHASECardiovascular Health: Astaxanthin Supplement Evaluation

● Randomized, double-blind, placebo controlled, GCP

● Subjects: Up to 360 (largest astaxanthin trial ever reported)

○ Cardiovascular risk factors○ C-reactive protein (CRP) > 2 mg/L

○ Standard of care

● Primary Endpoint: Cardiovascular inflammatory health as measured by CRP (change from baseline)

● Other Endpoints: Inflammatory markers, lipids, FOXO3, etc.

● ZanthoSyn® Dose: 0, 24, 96 mg

● Duration: 12 weeks

● First Subject Dosed: September 19, 2018

● Top Tier Leaders: Jon Ruckle, MD (PI of 350+ clinical trials); Deepak Bhatt, MD, Chair of REDUCE-IT trial with Amarin,head of Interventional Cardiology at BWH/Harvard

CARDAX SEEKING PARTNER FOR:

ZANTHOSYNPHARMACO-ECONOMIC STUDY?

TARGETING INFLAMMATORY HEALTH

Goal:

Substantially reduce costs in high utilizers by:

Impacting drug costs, side effects of other anti-inflammatory drugs

Reducing required procedures

CARDAX

ZANTHOSYNPHARMACO

TARGETING INFLAMMATORY

Goal:

PARTNER FOR:

ECONOMIC STUDY?

by:

other anti-inflammatory drugs

CERTAIN DISCLAIMERSThere are statements in this presentation that are not historical facts. These “forward-looking statements” can be identified by use ofterminology such as “anticipate,” “believe,” “estimate,” “expect,” “hope,” “intend,” “may,” “plan,” “positioned,” “project,” “propose,” “should,”“strategy,” “will,” “would,” or any similar expressions. You should be aware that these forward-looking statements are subject to risks anduncertainties that are beyond our control. For a discussion of these risks and their potential impact to the information provided in thispresentation, you should read the information that we have filed with the Securities and Exchange Commission, including the reports filedpursuant to the Securities Exchange Act of 1934, as amended, especially the risks discussed under the section entitled “Risk Factors”included in such reports. In light of these numerous risks and uncertainties, we cannot provide any assurance that the results and eventscontemplated by our forward-looking statements contained in this presentation will in fact transpire. You are cautioned to not place unduereliance on these forward-looking statements, which speak only as of their dates. We do not undertake any obligation to update or revise anyforward-looking statements.

Unless otherwise indicated, information contained in this presentation concerning our company, our business, the services we provide andintend to provide, our industry and our general expectations concerning our industry are based on management estimates. Such estimatesare derived from publicly available information released by third party sources, as well as data from our internal research, and reflectassumptions made by us based on such data and our knowledge of the industry, which we believe to be reasonable. However, we cannotprovide any assurance that these assumptions or estimates will be accurate or events that we expect will in fact transpire.

No securities are being offered by Cardax through this presentation. This presentation does not contain any material nonpublic informationabout or regarding Cardax. If you would like additional information, please contact Cardax.

* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.